1
|
Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, Sverdlov AL, Davies SW, Kindell LC, Anderson EJ. Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents. J Int Med Res 2018; 46:3183-3194. [PMID: 29808744 PMCID: PMC6134635 DOI: 10.1177/0300060518773934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Background Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.
Collapse
Affiliation(s)
- Jimmy T Efird
- 1 Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Charulata Jindal
- 1 Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Andy C Kiser
- 2 Department of Cardiovascular Sciences, Brody School of Medicine, Greenville, NC, USA
| | - Shahab A Akhter
- 2 Department of Cardiovascular Sciences, Brody School of Medicine, Greenville, NC, USA
| | - Patricia B Crane
- 3 Office of the Dean, College of Nursing, East Carolina University, Greenville, NC, USA
| | - Alan P Kypson
- 4 Cardiac Surgical Specialists, REX Health Care, University of North Carolina, Raleigh, NC, USA
| | - Aaron L Sverdlov
- 5 Priority Clinical Centre for Cardiovascular Health, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Stephen W Davies
- 6 Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Linda C Kindell
- 2 Department of Cardiovascular Sciences, Brody School of Medicine, Greenville, NC, USA
| | - Ethan J Anderson
- 7 Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, USA
| |
Collapse
|
2
|
Moazemi K, Chana JS, Willard AM, Kocheril AG. Intravenous vasodilator therapy in congestive heart failure. Drugs Aging 2003; 20:485-508. [PMID: 12749747 DOI: 10.2165/00002512-200320070-00002] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The prevalence of congestive heart failure (CHF) is increasing in the US and worldwide, partly because patients are living longer. Treatment of CHF is mostly on an outpatient basis, but inpatient care is required for decompensated CHF, acute CHF or poor response to outpatient treatment. Control of symptoms is usually achieved by diuresis. Intravenous (IV) vasodilators are an important adjunct to the inpatient treatment of CHF. They work mainly by reducing the afterload on the myocardium although preload reduction also occurs. After clinical stabilisation, the goal is to switch to a maintenance oral regimen to be continued as outpatient therapy. The range of IV vasodilators available for inpatient treatment of CHF includes nitrates, phosphodiesterase inhibitors, dobutamine, morphine, ACE inhibitors, B-type natriuretic peptides and endothelin receptor antagonists. As each agent may have a different mechanism or site of action, each agent may affect preload, contractility or afterload to a different extent and it may be desirable to choose one over the other in a particular clinical setting. Examples of standard therapy include dobutamine, milrinone and nitroglycerin. Nesiritide, a B-type natriuretic peptide, is a newer vasodilator and US FDA approved for use in acute CHF. However, most studies with this agent have been in small numbers of patients with anecdotal findings. Larger studies are warranted to pinpoint the efficacy and adverse effects of this agent. It is primarily used to reduce the acuity of decompensated CHF on admission to hospital.Endothelin receptor antagonists show promise in the management of acute CHF, but continue to be investigational. Long-term data on their efficacy and safety are limited. None of the endothelin receptor antagonists are FDA approved for use in patients with CHF.
Collapse
Affiliation(s)
- Kourosh Moazemi
- Carle Foundation Hospital, University of Illinois College of Medicine at Urbana-Champaign, Urbana, Illinois 61801, USA
| | | | | | | |
Collapse
|
3
|
Abstract
In recent years it has become clear that episodes of transient myocardial ischemia commonly occur in patients with coronary artery disease in the absence of chest pain or angina equivalent. These episodes of "silent myocardial ischemia" are particularly well documented during continuous ambulatory electrocardiographic monitoring in daily life. Evidence suggests that these episodes represent true ischemia, and appear to be a marker of unfavorable outcome. While the pathophysiology is not completely understood, it appears as though the mechanisms of angina and silent ischemia are the same. Both forms of ischemia respond to conventional antianginal medication. While long-acting nitrates are effective in reducing or preventing myocardial ischemia, because of their propensity to cause tolerance they should be used intermittently and in association with either beta-blockers or calcium antagonists. Nitrates are safe and comparatively inexpensive, and will continue to play an important role in the treatment and prevention of angina. However, in the light of current knowledge, there is no specific indication for the treatment of silent ischemia by nitrates.
Collapse
|
4
|
Grieve AP. Extending a Bayesian analysis of the two-period crossover to allow for baseline measurements. Stat Med 1994; 13:905-29. [PMID: 8047744 DOI: 10.1002/sim.4780130903] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In the context of a two-period crossover study with baseline measurements a graphical method is developed for displaying the dependence of posterior inferences concerning the treatment effect on unavoidable prior beliefs about the 'correct' model. The method is a generalization of the approach developed by Grieve for the corresponding case without baselines.
Collapse
Affiliation(s)
- A P Grieve
- Safety of Medicines Department, ZENECA Pharmaceuticals, Macclesfield, Cheshire, U.K
| |
Collapse
|
5
|
Jakob M, Rettig-Stürmer G, Stepien J. Isosorbide Dinitrate Solution Spray in Exercise-Induced Angina Pectoris. Clin Drug Investig 1993. [DOI: 10.1007/bf03259247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Deeg P. Antianginal Effect of Isosorbide-5-Mononitrate Given as Monotherapy in Angina Pectoris. Clin Drug Investig 1993. [DOI: 10.1007/bf03259248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|